COVID-19, RSV, and influenza immunizations show continued safety and substantial effectiveness against hospitalization across various populations.

As winter sets in, it brings with it a wave of familiar respiratory illnesses. Coupled with the pollution in many major ...

NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...

It may feel like you are surrounded by sniffles and coughs, but flu season activity is still low in many parts of the U.S.

Christmas, Kwanzaa, and other end-of-year holidays typically mean travel followed by close indoor contact with friends or loved ones — near-perfect conditions for nasty airborne viruses to spread. And ...

Sanofi ( ($SNY) ) just unveiled an update. In December 2025, Sanofi announced the completion of its acquisition of Vicebio Ltd, which enhances its ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments ...

GSK (GSK) stock is in focus as an expert panel of the European Medicines Agency ((EMA)) endorses the company's Arexvy RSV ...

Early-life viral infection programs immune cells to hijack allergy-associated maternal antibodies, driving allergy risk later ...

Last year's flu season between 2024-25 saw 542 flu-related deaths, which broke state records since record keeping began in ...

Federal officials say the U.S. Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and ...